These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 27074261)
21. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Crystal RG; Mastrangeli A; Sanders A; Cooke J; King T; Gilbert F; Henschke C; Pascal W; Herena J; Harvey BG Hum Gene Ther; 1995 May; 6(5):667-703. PubMed ID: 7578402 [No Abstract] [Full Text] [Related]
23. Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF. Egan ME Pediatr Pulmonol; 2021 Feb; 56 Suppl 1(Suppl 1):S32-S39. PubMed ID: 32681713 [TBL] [Abstract][Full Text] [Related]
24. A new era of personalized medicine for cystic fibrosis - at last! Quon BS; Wilcox PG Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544 [TBL] [Abstract][Full Text] [Related]
25. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Skilton M; Krishan A; Patel S; Sinha IP; Southern KW Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300 [TBL] [Abstract][Full Text] [Related]
26. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis. Schneider-Futschik EK Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators. Fajac I; Sermet I Cells; 2021 Oct; 10(10):. PubMed ID: 34685773 [TBL] [Abstract][Full Text] [Related]
28. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
29. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636 [TBL] [Abstract][Full Text] [Related]
30. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning. Barry PJ; Ronan N; Plant BJ Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594 [TBL] [Abstract][Full Text] [Related]
31. Gene therapy for cystic fibrosis: which postman, which box? Middleton PG; Alton EW Thorax; 1998 Mar; 53(3):197-9. PubMed ID: 9659356 [TBL] [Abstract][Full Text] [Related]
32. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. Beekman JM; Sermet-Gaudelus I; de Boeck K; Gonska T; Derichs N; Mall MA; Mehta A; Martin U; Drumm M; Amaral MD J Cyst Fibros; 2014 Jul; 13(4):363-72. PubMed ID: 24882694 [No Abstract] [Full Text] [Related]
33. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Sloane PA; Rowe SM Curr Opin Pulm Med; 2010 Nov; 16(6):591-7. PubMed ID: 20829696 [TBL] [Abstract][Full Text] [Related]
34. Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review. De la Hoz D; Villamil Osorio M; Restrepo-Gualteros SM Arch Argent Pediatr; 2019 Apr; 117(2):e131-e136. PubMed ID: 30869491 [TBL] [Abstract][Full Text] [Related]
35. Update on clinical trials of cystic fibrosis. Henig NR; Aitken ML Curr Opin Pulm Med; 1997 Nov; 3(6):404-9. PubMed ID: 9391758 [TBL] [Abstract][Full Text] [Related]
36. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
37. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Alton EW; Stern M; Farley R; Jaffe A; Chadwick SL; Phillips J; Davies J; Smith SN; Browning J; Davies MG; Hodson ME; Durham SR; Li D; Jeffery PK; Scallan M; Balfour R; Eastman SJ; Cheng SH; Smith AE; Meeker D; Geddes DM Lancet; 1999 Mar; 353(9157):947-54. PubMed ID: 10459902 [TBL] [Abstract][Full Text] [Related]